MedTrace Logo

Safety and Efficacy of Statins for Chinese Patients With Dyslipidemia

NCT03418974 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10000

Last updated 2018-02-01

No results posted yet for this study

Summary

This study is designed to verify the clinical efficacy and safety of different statins in dyslipidemia patients, and explore the effects on glycometabolic in patients with impaired glucose regulation.

Conditions

  • Dyslipidemias

Interventions

DRUG

Pitavastatin

Capsule/Tablet, oral, follow the doctor's advice Participants will receive pitavastatin treatment for 3 or 12 weeks.

DRUG

Atorvastatin

Capsule/Tablet, oral, follow the doctor's advice Participants will receive atorvastatin treatment for 3 or 12 weeks.

DRUG

Rosuvastatin

Capsule/Tablet, oral, follow the doctor's advice Participants will receive rosuvastatin treatment for 3 or 12 weeks.

Sponsors & Collaborators

  • Peking University People's Hospital

    collaborator OTHER

  • Jiangsu Wanbang Medicine Marketing Co., Ltd.

    collaborator UNKNOWN

  • Fudan University

    lead OTHER

Principal Investigators

  • Yuming Jin, Professor · School of Public Health，Fudan University

  • Dayi Hu, Professor · Director of Department of Cardiology, Peking University People's Hospital; Director of Institute of Cardiovascular Disease, Peking University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03418974 on ClinicalTrials.gov